MedTrace Logo

Effect of Rosuvastatin on Left Ventricular Remodeling

NCT00505154 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2014-01-27

No results posted yet for this study

Summary

The purpose of this study is to examine the the effect of the HMG-CoA reductase inhibitor Rosuvastatin on left ventricular remodeling in patients with dilated cardiomyopathy.

Conditions

  • Dilated Cardiomyopathy

Interventions

DRUG

Rosuvastatin

Rosuvastatin 10 mg tablets od for 6 months

DRUG

placebo

placebo

Sponsors & Collaborators

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Geir Gokstad · Rikshospitalet, Oslo, Norway

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00505154 on ClinicalTrials.gov